Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma

Inclusion Criteria:

1. Age greater than or equal to 18 years old, male or female;

2. Relapsed or refractory CNS-involved large b-cell lymphoma after at least first-linetherapy, with an efficacy assessment of CR or PR after salvage therapy, and currentstable efficacy status;

3. Eastern Cooperative Oncology Group (ECOG) score of 0-2;

4. Have a life expectancy of ≥ 12 weeks

5. Use contraception

6. Have adequate bone marrow and organ function:

7. Neutrophil count (anc) ≥1.0 x 109/L;

8. Hemoglobin ≥ 8.0 g/dl;

9. Platelet count ≥ 50 x 109/L;

10. Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

11. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 x ULN or ≤ 5 x ULN (in the presence of hepatic invasion);

12. Creatinine clearance ≥40mL/min

13. Lipase ≤ 1.5 x ULN

Exclusion Criteria:

1. Severe active central nervous system symptoms

2. Prior chimeric antigen receptor cellular immunotherapy targeting cd19

3. Known human immunodeficiency virus (hiv) infection or positive immunoassay;

4. Live vaccination within 30 days prior to study drug administration;

5. Active autoimmune disease requiring systemic therapy in the last 12 months

6. Allergy to the study drug or history of severe allergic reactions

7. Potential risk of malignant cardiac arrhythmia

8. History of stroke or intracranial hemorrhage within 3 months prior to the date ofadministration of study medication

9. Other malignant tumors presently or within 3 years prior to enrollment

10. Conditions that, in the judgment of the investigator, would interfere with fullparticipation in the study; pose a significant risk to the subject; or interferewith the interpretation of the study data

11. Pregnant or lactating patients;